|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Mental Health (NIMH) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00942981 |
Purpose
Background:
Objectives:
- To study the amount and distribution of two types of dopamine receptors.
Eligibility:
Design:
| Condition |
|---|
|
Schizoaffective Disorder Schizophrenia |
| Study Type: | Observational |
| Official Title: | Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography |
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
EXCLUSION CRITERIA: (for patients and controls except where indicated)
Contacts and Locations| Contact: Jasmin Czarapata, Ph.D. | (301) 435-7645 | js733c@nih.gov |
| Contact: Karen F Berman, M.D. | (301) 496-7603 | bermank@mail.nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 prpl@mail.cc.nih.gov | |
| Principal Investigator: | Karen F Berman, M.D. | National Institute of Mental Health (NIMH) |
More Information
| ClinicalTrials.gov Identifier: | NCT00942981 History of Changes |
| Other Study ID Numbers: | 090176, 09-M-0176 |
| Study First Received: | July 18, 2009 |
| Last Updated: | March 20, 2012 |
| Health Authority: | United States: Federal Government |
|
PET Study (18F) Fallypride (11C)NNC-112 Schizoaffective Disorder |
Schizophrenia Healthy Volunteer HV |
|
Psychotic Disorders Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Dopamine Cardiotonic Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions |
Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents |